Laurel Wealth Advisors (California)’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$497K	Sell	1,722 -18	-1%	-$5.49K	0.05%	358
2022 Q3	$504K	Sell	1,740 -461	-21%	-$133K	0.05%	340
2022 Q2	$621K	Sell	2,201 -472	-18%	-$126K	0.06%	311
2022 Q1	$698K	Sell	2,673 -238	-8%	-$56.5K	0.06%	329
2021 Q4	$639K	Buy	+2,911	New	+$566K	0.05%	371

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Laurel Wealth Advisors (California)'s VRTX Position: Q4 2022 in Review

Laurel Wealth Advisors (California) reduced its Vertex Pharmaceuticals (VRTX) stake by 1% in Q4 2022, selling an estimated $5.49K and leaving 1,722 shares worth $497K. The position accounts for 0.05% of the portfolio, ranked #358.

Laurel Wealth Advisors (California) first reported a position in VRTX in Q4 2021 and has held it in 5 quarters since. The position peaked at $698K in Q1 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Laurel Wealth Advisors (California) held 1,722 shares of Vertex Pharmaceuticals worth $497K as of Q4 2022.
Laurel Wealth Advisors (California) sold 18 Vertex Pharmaceuticals shares in Q4 2022, an estimated $5.49K.
Vertex Pharmaceuticals made up 0.05% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #358 holding.
Laurel Wealth Advisors (California) first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Laurel Wealth Advisors (California)'s Vertex Pharmaceuticals position peaked at $698K in Q1 2022.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.